figshare
Browse
13058_2019_1221_MOESM1_ESM.xlsx (20.04 kB)

MOESM1 of Prediction and clinical utility of a contralateral breast cancer risk model

Download (20.04 kB)
dataset
posted on 2019-12-18, 07:23 authored by Daniele Giardiello, Ewout Steyerberg, Michael Hauptmann, Muriel Adank, Delal Akdeniz, Carl Blomqvist, Stig Bojesen, Manjeet Bolla, Mariël Brinkhuis, Jenny Chang-Claude, Kamila Czene, Peter Devilee, Alison Dunning, Douglas Easton, Diana Eccles, Peter Fasching, Jonine Figueroa, Henrik Flyger, Montserrat García-Closas, Lothar Haeberle, Christopher Haiman, Per Hall, Ute Hamann, John Hopper, Agnes Jager, Anna Jakubowska, Audrey Jung, Renske Keeman, Iris Kramer, Diether Lambrechts, Loic Marchand, Annika Lindblom, Jan Lubiński, Mehdi Manoochehri, Luigi Mariani, Heli Nevanlinna, Hester Oldenburg, Saskia Pelders, Paul Pharoah, Mitul Shah, Sabine Siesling, Vincent Smit, Melissa Southey, William Tapper, Rob Tollenaar, Alexandra Broek, Carolien Deurzen, Flora Leeuwen, Chantal Ongeval, Laura Van’t Veer, Qin Wang, Camilla Wendt, Pieter Westenend, Maartje Hooning, Marjanka Schmidt
Additional file 1 Table S1. Data source flowchart. Table S2. Description of the studies included in the analyses. Table S3. Patients and first primary breast cancer characteristics used in the contralateral breast cancer risk prediction model in the complete case and all case analyses. Table S4. Results of multivariable subdistributional hazard model using the complete case dataset. Table S5. List of BCAC studies (including ABCS source) with the corresponding country and geographic area. Table S6. Main patient and disease characteristics. Table S7. Clinical utility of the 5-year contralateral breast cancer risk prediction model. Table S8. Results of multivariable subdistributional hazard model for breast cancer patients without BRCA mutations. Table S9. Clinical utility of the 5-year contralateral breast cancer risk prediction model in non-BRCA tested patients. Table S10. Clinical utility of the 10-year contralateral breast cancer risk prediction model in non-BRCA tested patients.

Funding

KWF Kankerbestrijding

History